Patents by Inventor W. Michael Kavanaugh

W. Michael Kavanaugh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210100913
    Abstract: Provided herein are activatable antibodies that specifically bind to CD166 and conjugated activatable antibodies that specifically bind to CD166. Also provided are methods of making and using these activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: July 21, 2020
    Publication date: April 8, 2021
    Inventors: Lori CARMAN, Rachel HUMPHREY, W. Michael KAVANAUGH, Jonathan TERRETT, Annie Yang WEAVER, Matthias WILL
  • Publication number: 20210020264
    Abstract: The present invention provides methods and systems useful for modeling the pharmacology of an activated binding polypeptide or activatable antibody in a mammalian subject.
    Type: Application
    Filed: March 20, 2019
    Publication date: January 21, 2021
    Inventors: Mark Anthony Stroh, Jason Gary Sagert, Joshua F. Apgar, Bjorn L. Millard, Lin Lin, John M. Burke, W. Michael Kavanaugh
  • Publication number: 20190117789
    Abstract: Provided herein are activatable antibodies that specifically bind to CD166 and conjugated activatable antibodies that specifically bind to CD166. Also provided are methods of making and using these activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: August 30, 2018
    Publication date: April 25, 2019
    Inventors: LORI CARMAN, RACHEL HUMPHREY, W. MICHAEL KAVANAUGH, JONATHAN TERRETT, ANNIE YANG WEAVER, MATTHIAS WILL
  • Publication number: 20180221446
    Abstract: The present invention provides a unit dose comprising 0.2 ?g/kg to 36 ?g/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of said patient a safe and angiogenically effective dose of a recombinant FGF of any of SEQ ID NOS: 1-3, 5, 8-10, or 12-14, or an angiogenically active fragment or mutein thereof.
    Type: Application
    Filed: September 8, 2017
    Publication date: August 9, 2018
    Applicant: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Martha J. Whitehouse, W. Michael Kavanaugh
  • Publication number: 20180016555
    Abstract: Methods of identifying and using SLAMF1 antagonists are provided.
    Type: Application
    Filed: October 21, 2015
    Publication date: January 18, 2018
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Luis Borges, Nathan Sallee, Charles Kaplan, Arthur Brace, W. Michael Kavanaugh, Brian Wong, David Bellovin, Thomas Brennan, Artur Karasyov
  • Publication number: 20160120943
    Abstract: The present invention provides a unit dose comprising 0.2 ?g/kg to 36 ?g/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of said patient a safe and angiogenically effective dose of a recombinant FGF of any of SEQ ID NOS:1-3, 5, 8-10, or 12-14, or an angiogenically active fragment or mutein thereof.
    Type: Application
    Filed: September 28, 2015
    Publication date: May 5, 2016
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventors: Martha J. Whitehouse, W. Michael Kavanaugh
  • Patent number: 9169313
    Abstract: The present invention relates to the use of Fibroblast Growth Factor Receptor I (FGFR1) extracellular domain (ECD) polypeptides for treatment of cancers characterized by ligand dependent activating mutations in Fibroblast Growth Factor Receptor 2 (FGFR2). For example, the present invention relates to the treatment of endometrial cancers and other cancers wherein tumor cells express FGFR2 mutants in the IgII-IgIII hinge region or IgIII domain of the protein, such as at amino acid positions 252 and/or 253.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: October 27, 2015
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Thomas Harding, W. Michael Kavanaugh
  • Patent number: 9149507
    Abstract: The present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of said patient a safe and angiogenically effective dose of a recombinant FGF-9 of SEQ ID NO:13, or an angiogenically active fragment or mutein thereof. The invention is also directed to a method for inducing angiogenesis in the heart of a patient, comprising administering into at least one coronary vessel of a human patient in need of coronary angiogenesis a therapeutically effective amount of a recombinant FGF-9 of SEQ ID NO:13, or an angiogenically active fragment or mutein thereof.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: October 6, 2015
    Assignee: Novartis Vaccines and Dignostics, Inc.
    Inventors: Martha J. Whitehouse, W. Michael Kavanaugh
  • Publication number: 20140274898
    Abstract: The present invention relates to a method of promoting hair growth comprising administering a fibroblast growth factor receptor 3 (FGFR3) extracellular domain (ECD), including native FGFR3 ECDs, variants, fragments, and fusion molecules, to a subject in an amount sufficient to promote hair growth.
    Type: Application
    Filed: February 20, 2014
    Publication date: September 18, 2014
    Applicant: FIVE PRIME THERAPEUTICS, INC.
    Inventors: Thomas Brennan, Robert Dean, W. Michael Kavanaugh, Janine Powers
  • Publication number: 20140227263
    Abstract: The present invention relates to the use of Fibroblast Growth Factor Receptor I (FGFR1) extracellular domain (ECD) polypeptides for treatment of cancers characterized by ligand dependent activating mutations in Fibroblast Growth Factor Receptor 2 (FGFR2). For example, the present invention relates to the treatment of endometrial cancers and other cancers wherein tumor cells express FGFR2 mutants in the IgII-IgIII hinge region or IgIII domain of the protein, such as at amino acid positions 252 and/or 253.
    Type: Application
    Filed: November 14, 2013
    Publication date: August 14, 2014
    Applicant: FIVE PRIME PHARMACEUTICALS, INC.
    Inventors: Thomas Harding, W. Michael Kavanaugh
  • Publication number: 20140142038
    Abstract: The present invention provides a unit dose comprising 0.2 ?g/kg to 36 ?g/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of said patient a safe and angiogenically effective dose of a recombinant FGF of any of SEQ ID NOS:1-3, 5, 8-10, or 12-14, or an angiogenically active fragment or mutein thereof.
    Type: Application
    Filed: December 6, 2013
    Publication date: May 22, 2014
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventors: Martha J. Whitehouse, W. Michael Kavanaugh
  • Patent number: 8685931
    Abstract: The present invention relates to a method of promoting hair growth comprising administering a fibroblast growth factor receptor 3 (FGFR3) extracellular domain (ECD), including native FGFR3 ECDs, variants, fragments, and fusion molecules, to a subject in an amount sufficient to promote hair growth.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: April 1, 2014
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Thomas Brennan, Robert Dean, W. Michael Kavanaugh, Janine Powers
  • Patent number: 8618052
    Abstract: The present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of a human patient in need of treatment for coronary artery disease a safe and angiogenically effective dose of a recombinant FGF-5 of SEQ ID NO:9, or an angiogenically active fragment or mutein thereof. The invention is also directed to a method for inducing angiogenesis in the heart of a patient, comprising administering into at least one coronary vessel of a human patient in need of coronary angiogenesis a therapeutically effective amount of a recombinant FGF-5 of SEQ ID NO:9, or an angiogenically active fragment or mutein thereof.
    Type: Grant
    Filed: November 17, 2010
    Date of Patent: December 31, 2013
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Martha J. Whitehouse, W. Michael Kavanaugh
  • Patent number: 8614183
    Abstract: The present invention relates to the use of Fibroblast Growth Factor Receptor I (FGFR1) extracellular domain (ECD) polypeptides for treatment of cancers characterized by ligand dependent activating mutations in Fibroblast Growth Factor Receptor 2 (FGFR2). For example, the present invention relates to the treatment of endometrial cancers and other cancers wherein tumor cells express FGFR2 mutants in the IgII-IgIII hinge region or IgIII domain of the protein, such as at amino acid positions 252 and/or 253.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: December 24, 2013
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Thomas Harding, W. Michael Kavanaugh
  • Patent number: 8445445
    Abstract: The present invention relates to a method of promoting hair growth comprising administering a fibroblast growth factor receptor 4 (FGFR4) extracellular domain (ECD), including native FGFR4 ECDs, variants, fragments, and fusion molecules, to a subject in an amount sufficient to promote hair growth.
    Type: Grant
    Filed: September 15, 2010
    Date of Patent: May 21, 2013
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Thomas Brennan, Robert Dean, W. Michael Kavanaugh, Janine Powers
  • Publication number: 20130058928
    Abstract: The present invention relates to a method of promoting hair growth comprising administering a fibroblast growth factor receptor 3 (FGFR3) extracellular domain (ECD), including native FGFR3 ECDs, variants, fragments, and fusion molecules, to a subject in an amount sufficient to promote hair growth.
    Type: Application
    Filed: December 17, 2010
    Publication date: March 7, 2013
    Applicant: FIVE PRIME THERAPEUTICS, INC.
    Inventors: Thomas Brennan, Robert Dean, W. Michael Kavanaugh, Janine Powers
  • Publication number: 20120183541
    Abstract: The present invention relates to a method of promoting hair growth comprising administering a fibroblast growth factor receptor 4 (FGFR4) extracellular domain (ECD), including native FGFR4 ECDs, variants, fragments, and fusion molecules, to a subject in an amount sufficient to promote hair growth.
    Type: Application
    Filed: September 15, 2010
    Publication date: July 19, 2012
    Inventors: Thomas Brennan, Robert Dean, W. Michael Kavanaugh, Janine Powers
  • Publication number: 20120165245
    Abstract: The present invention provides a unit dose comprising 0.2 ?g/kg to 36 ?g/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of said patient a safe and angiogenically effective dose of a recombinant FGF of any of SEQ ID NOS:1-3, 5, 8-10, or 12-14, or an angiogenically active fragment or mutein thereof.
    Type: Application
    Filed: November 17, 2010
    Publication date: June 28, 2012
    Applicant: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Martha J. Whitehouse, W. Michael Kavanaugh
  • Patent number: 8178493
    Abstract: The present invention has multiple aspects. In one aspect, the present invention is directed to a unit dose pharmaceutical composition comprising from about 5 ng/dose to less than 135,000 ng of an angiogenic agent, typically from 5 ng to 67,500 ng. Preferably, the angiogenic agent is FGF, more preferably it is basic FGF (FGF-2). In its second aspect, the present invention is directed to a method for inducing angiogenesis, or increasing myocardial perfusion or vascular density in a patient's heart, comprising administering directly into the myocardium in an area in need, as a single injection or a series of injections, a unit dose of an angiogenic agent. It is also within the scope of the present invention that a plurality of unit dose compositions be administered directly into the myocardium at a plurality of sites in need of angiogenesis.
    Type: Grant
    Filed: April 6, 2009
    Date of Patent: May 15, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: David T. Hung, Brian H. Annex, Kevin P. Landolfo, W. Michael Kavanaugh
  • Patent number: 7858584
    Abstract: The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose comprising 0.2 ?g/kg to 36 ?g/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. In another aspect, the present invention is directed to a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Typically, the angiogenically effective dose comprises 0.2 ?g/kg to 36 ?g/kg of an FGF of any one of SEQ ID NOS:1-3, 5, 8-10, or 12-14 or an angiogenically active fragment or mutein thereof.
    Type: Grant
    Filed: February 24, 2009
    Date of Patent: December 28, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Martha J. Whitehouse, W. Michael Kavanaugh